The role of cyclosporin in prolonging survival in vascularized bone allografts

James P. Paskert, Michael J. Yaremchuk, Mark A. Randolph, Andrew J. Weiland

Research output: Contribution to journalArticle

Abstract

It is known that experimental vascularized bone allo-grafts are subject to host rejection. To be useful clinically, this rejection response would need to be controlled. Cyclosporin is a potent immunosuppressant whose precise role in vascularized bone allograft transplantation has not been established. Using a proven reliable vascularized knee allograft model in inbred rats, cyclosporin was used postoperatively both continuously and short term (14 days after transplant) at 10 mg/kg per day as recipient treatment. Across a strong histocompatibility barrier, continuous cyclosporin was required for long-term graft survival. Short-term therapy delayed rejection for 4 to 6 weeks. However, across a weak histocompatibility barrier, short-term therapy was as effective as continuous therapy in achieving long-term graft survival. The implication is that a limited course of cyclosporin may be clinically successful in sustaining vascularized bone allograft survival, provided the genetic disparity between graft and host has been minimized by genetic matching techniques.

Original languageEnglish (US)
Pages (from-to)240-247
Number of pages8
JournalPlastic and Reconstructive Surgery
Volume80
Issue number2
StatePublished - 1987

Fingerprint

Cyclosporine
Allografts
Bone and Bones
Histocompatibility
Graft Survival
Transplants
Genetic Techniques
Bone Transplantation
Therapeutics
Immunosuppressive Agents
Knee

ASJC Scopus subject areas

  • Surgery

Cite this

Paskert, J. P., Yaremchuk, M. J., Randolph, M. A., & Weiland, A. J. (1987). The role of cyclosporin in prolonging survival in vascularized bone allografts. Plastic and Reconstructive Surgery, 80(2), 240-247.

The role of cyclosporin in prolonging survival in vascularized bone allografts. / Paskert, James P.; Yaremchuk, Michael J.; Randolph, Mark A.; Weiland, Andrew J.

In: Plastic and Reconstructive Surgery, Vol. 80, No. 2, 1987, p. 240-247.

Research output: Contribution to journalArticle

Paskert, JP, Yaremchuk, MJ, Randolph, MA & Weiland, AJ 1987, 'The role of cyclosporin in prolonging survival in vascularized bone allografts', Plastic and Reconstructive Surgery, vol. 80, no. 2, pp. 240-247.
Paskert, James P. ; Yaremchuk, Michael J. ; Randolph, Mark A. ; Weiland, Andrew J. / The role of cyclosporin in prolonging survival in vascularized bone allografts. In: Plastic and Reconstructive Surgery. 1987 ; Vol. 80, No. 2. pp. 240-247.
@article{bbd44d659bcd4db982438ff5f93dd285,
title = "The role of cyclosporin in prolonging survival in vascularized bone allografts",
abstract = "It is known that experimental vascularized bone allo-grafts are subject to host rejection. To be useful clinically, this rejection response would need to be controlled. Cyclosporin is a potent immunosuppressant whose precise role in vascularized bone allograft transplantation has not been established. Using a proven reliable vascularized knee allograft model in inbred rats, cyclosporin was used postoperatively both continuously and short term (14 days after transplant) at 10 mg/kg per day as recipient treatment. Across a strong histocompatibility barrier, continuous cyclosporin was required for long-term graft survival. Short-term therapy delayed rejection for 4 to 6 weeks. However, across a weak histocompatibility barrier, short-term therapy was as effective as continuous therapy in achieving long-term graft survival. The implication is that a limited course of cyclosporin may be clinically successful in sustaining vascularized bone allograft survival, provided the genetic disparity between graft and host has been minimized by genetic matching techniques.",
author = "Paskert, {James P.} and Yaremchuk, {Michael J.} and Randolph, {Mark A.} and Weiland, {Andrew J.}",
year = "1987",
language = "English (US)",
volume = "80",
pages = "240--247",
journal = "Plastic and Reconstructive Surgery",
issn = "0032-1052",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - The role of cyclosporin in prolonging survival in vascularized bone allografts

AU - Paskert, James P.

AU - Yaremchuk, Michael J.

AU - Randolph, Mark A.

AU - Weiland, Andrew J.

PY - 1987

Y1 - 1987

N2 - It is known that experimental vascularized bone allo-grafts are subject to host rejection. To be useful clinically, this rejection response would need to be controlled. Cyclosporin is a potent immunosuppressant whose precise role in vascularized bone allograft transplantation has not been established. Using a proven reliable vascularized knee allograft model in inbred rats, cyclosporin was used postoperatively both continuously and short term (14 days after transplant) at 10 mg/kg per day as recipient treatment. Across a strong histocompatibility barrier, continuous cyclosporin was required for long-term graft survival. Short-term therapy delayed rejection for 4 to 6 weeks. However, across a weak histocompatibility barrier, short-term therapy was as effective as continuous therapy in achieving long-term graft survival. The implication is that a limited course of cyclosporin may be clinically successful in sustaining vascularized bone allograft survival, provided the genetic disparity between graft and host has been minimized by genetic matching techniques.

AB - It is known that experimental vascularized bone allo-grafts are subject to host rejection. To be useful clinically, this rejection response would need to be controlled. Cyclosporin is a potent immunosuppressant whose precise role in vascularized bone allograft transplantation has not been established. Using a proven reliable vascularized knee allograft model in inbred rats, cyclosporin was used postoperatively both continuously and short term (14 days after transplant) at 10 mg/kg per day as recipient treatment. Across a strong histocompatibility barrier, continuous cyclosporin was required for long-term graft survival. Short-term therapy delayed rejection for 4 to 6 weeks. However, across a weak histocompatibility barrier, short-term therapy was as effective as continuous therapy in achieving long-term graft survival. The implication is that a limited course of cyclosporin may be clinically successful in sustaining vascularized bone allograft survival, provided the genetic disparity between graft and host has been minimized by genetic matching techniques.

UR - http://www.scopus.com/inward/record.url?scp=0023640006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023640006&partnerID=8YFLogxK

M3 - Article

C2 - 3299419

AN - SCOPUS:0023640006

VL - 80

SP - 240

EP - 247

JO - Plastic and Reconstructive Surgery

JF - Plastic and Reconstructive Surgery

SN - 0032-1052

IS - 2

ER -